AU · rank #4 · 2026-10-23
ATEC
NASDAQ · $1.68B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.717 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.00 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $1,013,150 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $15.79 | +39.0% |
| Momentum acceleration 3-month minus 12-month momentum. | +44.66% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.79 |
| Gross margin TTM | +70.8% |
| 52w high | $23.29 |
| Market cap (USD) | $1.68B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Alphatec Holdings is a spine-focused medical devices company selling integrated implants, imaging, and analytics systems under Alphatec Spine, EOS, SafeOp, and InformatiX, with 2026 revenue guided to about $882 million.
Rationale
The quant setup is reinforced by very high sell-side upside (~39%), a strong average analyst rating, solid revision agreement, accelerating share-price momentum, and improving operating traction with Q2 revenue up 15% and adjusted EBITDA guidance raised to about $140 million.
Material risks
- 1ATEC faces intense competition from larger bundled-platform peers like Medtronic, Globus Medical, Stryker, and Zimmer Biomet, which could slow adoption or force pricing pressure because ATEC lacks sole-source or contracted revenue visibility.
- 2The company still carries GAAP losses and meaningful leverage, so execution misses on surgeon adoption, reimbursement, or the 2026 plan could quickly pressure the upside case.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.